Viridian Therapeutics announces the price of its public offering

WALTHAM, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) – Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company providing new treatments for patients with serious illnesses but underserved by current therapies, announced today hui the price of a public offering subscribed with gross proceeds of approximately $ 85.0 million. Viridian sells a total of 6,185,454 common shares at a public offering price of $ 11.00 per share and 23,126 Series B preferred shares (the “Preferred Series B”) at a public offering price of 733 , $ 37 per share, which is convertible into approximately 1,541,810 common shares, subject to beneficial ownership conversion limits. In addition, Viridian has granted the underwriters a 30-day option to purchase an additional 1,159,089 common shares at the public offering price less rebates and underwriting fees.

All the shares that will be sold as part of the subscribed public offer are offered by Viridian. The offer is expected to close on or around September 23, 2021, subject to customary closing conditions.

Viridian intends to use the proceeds of its share tender offer to advance the development of its VRDN-001 and VRDN-002 programs and the preclinical development of its VRDN-004 and VRDN-005 programs. , as well as for working capital and general corporate purposes.

Jefferies, SVB Leerink and Evercore ISI act as co-book managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission (SEC) and became effective on April 14, 2020. A final prospectus supplement relating to and describing the terms of the offer will be filed with the SEC. The securities described above have not been qualified under any state’s blue sky laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy such securities, and there will be no sale of such securities in any State or other jurisdiction in which such an offer, solicitation or sale would be illegal prior to registration or qualification under the securities laws of any such state or other jurisdiction. The offering may only be made by way of prospectus, copies of which can be obtained from the SEC’s website at, or upon request to Jefferies LLC (Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022; phone: 877-821-7388; email: [email protected]), SVB Leerink LLC (Attention: Syndicate Department, 53 State Street, 40th Floor , Boston, MA 02109; phone: 800-808-7525, ext 6105; email: [email protected]), or Evercore Group LLC (Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055; phone: 888-474-0200; email: [email protected]om).

About Viridian Therapeutics, Inc.

Viridian Therapeutics is a biotechnology company providing new treatments for patients with serious illnesses but underserved by current therapies. Viridian’s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED), a self-debilitating disease. immune disease that causes inflammation and fibrosis in the eye socket that can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple corrective surgeries of the eye socket, eye muscles, and eyelids. Viridian is based in Waltham, Massachusetts.

Note regarding forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, “anticipate”, “believe”, “Continue”, “” could “,” estimate “,” expect “,” intend “,” could “,” could “,” plan “,” potential “,” foresee “,” plan ” , “should”, “target”, “will”, or “would” or other similar words or expressions that relate to our expectations, plans and intentions. Forward-looking statements include, but are not limited to, statements regarding the proposed public subscribed offer and the Company’s expectations regarding the use of the net proceeds of the proposed public subscribed offer. Forward-looking statements are neither historical facts nor guarantees of future performance. Instead, they are based on our current beliefs, expectations and assumptions. s and uncertainties may appear from time to time, and it is not possible to predict all risks and uncertainties. No representation or warranty (express or implied) is made as to the accuracy of these forward-looking statements. These forward-looking statements are subject to a number of significant risks and uncertainties, including, but not limited to: satisfaction of customary closing conditions relating to the proposed public offering subscribed; and other risks and uncertainties identified in our documents filed with the SEC, including the risks set out under “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC ) August 12, 2021 and other subsequent disclosure documents filed with the SEC. Any forward-looking statement speaks only as of the date on which it is made. Neither we, nor our affiliates, advisers or representatives, undertake to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. required. These forward-looking statements should not be taken as representing our views as of any date subsequent to the date hereof.

Viridian contacts:

Dan Ferry
LifeSci Advisors
[email protected]

Darby Pearson
Verge Scientific Communications
[email protected]

Source: Viridian Therapeutics, Inc.

Comments are closed.